# Xylyx Bio Gets FDA Orphan Designation And NIH Grant

> Xylyx Bio receives FDA orphan drug status and $2.99m NIH grant for Inspirex Lung.
- Title: Xylyx Bio Gets FDA Orphan Designation And NIH Grant | Shortify
- Summary: Xylyx Bio receives FDA orphan drug status and $2.99m NIH grant for Inspirex Lung. Xylyx Bio's Inspirex Lung, a bioengineered lung graft for patients with…
- Keywords: xylyx bio, inspirex lung, fda orphan drug designation, nih grant, bioengineered lung graft, lung transplantation, startups, business, Xylyx, Bio, Gets, FDA
- Source: Pulse 2.0 — https://pulse2.com/xylyx-bio-receives-fda-orphan-drug-designation-and-2-99-million-nih-grant-for-inspirex-lung
- Author: Amit Chowdhry
- Published: 2026-10-20T20:30:01+00:00
- Read time: 1 min
- Topics: xylyx bio, inspirex lung, fda orphan drug designation, nih grant, bioengineered lung graft, lung transplantation, startups, business
## FDA Orphan Designation
Xylyx Bio receives FDA orphan drug designation for Inspirex Lung.
## NIH Grant Funding
NIH provides $2.99 million for Inspirex Lung safety and feasibility studies.
## Inspirex Lung Purpose
Inspirex Lung repairs injured donor lungs to increase transplant availability.
## Key takeaway

Xylyx Bio's Inspirex Lung, a bioengineered lung graft for patients with lung failure, gets FDA orphan drug designation and $2.99 million NIH grant to advance development.